AGIO vs CRSP: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
CRSP is the larger of the two ($3.81B market cap): the incumbent the market prices for continued execution (a loss expected next year, beta 1.90). AGIO is the smaller challenger ($1.69B), also expected to post a loss next year: more room to run, but more to prove. If you believe in growth, CRSP fits: analysts expect its revenue to rise 265% next year, against 88% for AGIO. If you believe AGIO's main driver (Mitapivat franchise expansion) pays off sooner, AGIO fits.
AGIO vs CRSP: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | AGIO | CRSP | What it tells you |
|---|---|---|---|
| Market cap | $1.69B | $3.81B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | -9.14 | -10.67 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.62 | 1.90 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 25% of range | 4% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 1.73 | 2.31 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how AGIO and CRSP affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AGIO and CRSP share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AGIO and CRSP exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Agios Pharmaceuticals (AGIO) do?
Agios Pharmaceuticals develops medicines for rare hematologic (blood) diseases. Its lead product, mitapivat, is an oral pyruvate kinase (PK) activator sold as PYRUKYND for PK deficiency and, following a 2026 approval, as AQVESME for thalassemia (US launch January 2026; PYRUKYND was also approved for thalassemia in the EU in late May 2026). The company is pursuing accelerated approval of mitapivat in sickle cell disease. The FDA granted Priority Review to that application in 2026 with a decision expected by November 1, 2026, but in late October it extended the goal date by three months to February 1, 2027, after asking for more information on whether a REMS (a formal risk-management program) is needed and classifying Agios' response as a major amendment. Agios previously sold its oncology business to Servier in 2021, which left it focused purely on hematology and entitled to a royalty on US net sales of Servier's brain-cancer drug Voranigo (vorasidenib).
What does CRISPR Therapeutics AG (CRSP) do?
CRISPR Therapeutics AG is a Swiss-American biopharmaceutical company headquartered in Zug, Switzerland, with principal research operations in Boston, Massachusetts. The company uses its proprietary CRISPR/Cas9 platform to develop gene-based medicines across hemoglobinopathies, oncology, cardiovascular disease, autoimmune conditions, and regenerative medicine. Its first and only commercialized product, Casgevy, is co-developed and co-commercialized with Vertex Pharmaceuticals under a 40/60 profit-sharing structure in which CRISPR retains 40 percent of profits. Revenue has historically been driven by collaboration milestone payments from Vertex rather than product sales, making the financial profile highly lumpy. Beyond Casgevy, the company generates no meaningful product revenue today and funds operations through its cash reserves.
AGIO vs CRSP: how do they differ?
Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.
- AGIO drivers: Mitapivat franchise expansion; Sickle cell decision, now February 2027.
- CRSP drivers: First-Mover Advantage in Commercial Gene Editing; Casgevy's Long-Term Revenue Potential.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Agios remains deeply unprofitable, reporting a quarterly GAAP loss of $1.09 per share in Q3 2026 and about $373 million of net losses over the trailing year, while product revenue is still modest at about $141 million over the same period. For CRSP, the commercial ramp of Casgevy has been far slower than early projections: CRSP's reported revenue was only about $3.5 million in all of 2025, down sharply from prior years that were boosted by one-time milestone payments, and only about $25 million over the twelve months to September 2026.
AGIO or CRSP: which should you pick?
If the story you believe is AGIO's (Mitapivat franchise expansion), AGIO is the more direct way to own it; if it is CRSP's (First-Mover Advantage in Commercial Gene Editing), CRSP is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AGIO and CRSP guides.
AGIO vs CRSP: the full fundamentals
AGIO. Agios trades at about 12 times trailing revenue, down from about 19 times in October as sales grew and the stock fell on the FDA extension, and the valuation still rests on the sickle cell opportunity rather than current earnings. Analysts expect revenue of about $185 million in 2026 and $349 million in 2027, with losses narrowing to about -$3.00 per share in 2027. The nine covering analysts carry a buy rating and a mean target of about $46 (BofA trimmed its target to $48 from $50 after the quarter), well above the price.
CRSP. Because CRISPR Therapeutics has no meaningful product profits yet, traditional earnings-based multiples like P/E are negative and not analytically useful; the company is better evaluated on cash runway, Casgevy adoption, and the risk-adjusted value of its pipeline. Market cap of about $3.8 billion less roughly $1.5 billion of net cash leaves an enterprise value near $2.3 billion, down from about $3.3 billion a month earlier, which reflects significant execution uncertainty. Targets remain widely spread, from UBS at $52 to a consensus mean near $85, both well above the November 20 close.
Headline figures (approximate, November 2026): AGIO shows revenue (ttm) ~$141M, q3 2026 revenue ~$55.4M (vs ~$12.9M a year earlier), ahead of ~$52M expected, q3 2026 eps ~-$1.09 vs ~-$1.23 expected, net loss (ttm) ~-$373M; free cash flow ~-$264M; CRSP shows revenue (ttm to sep 30, 2026) ~$25 million (Q3 2026 ~$12.7 million), revenue (full year 2025) ~$3.5 million, net loss (ttm) ~$456 million; Q3 2026 ~$111 million, eps (q3 2026, actual vs estimate) -$1.15 vs -$1.06.
The bottom line: AGIO vs CRSP
AGIO and CRSP are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined AGIO and CRSP exposure against your real portfolio. It is not an investment adviser.
Wondering how AGIO or CRSP fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Agios Pharmaceuticals
Ask Walnut's AI anything about AGIO and see how it fits what you own.
FAQ
What is the difference between AGIO and CRSP?
+
Agios Pharmaceuticals develops medicines for rare hematologic (blood) diseases. CRISPR Therapeutics AG is a Swiss-American biopharmaceutical company headquartered in Zug, Switzerland, with principal research operations in Boston, Massachusetts. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is AGIO or CRSP the better stock?
+
Neither is universally better. CRSP is the larger incumbent; AGIO is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, AGIO or CRSP?
+
A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both AGIO and CRSP?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of AGIO vs CRSP?
+
AGIO: Agios remains deeply unprofitable, reporting a quarterly GAAP loss of $1.09 per share in Q3 2026 and about $373 million of net losses over the trailing year, while product revenue is still modest at about $141 million over the same period. The business now depends almost entirely on a single molecule, so a negative trial or regulatory setback is materially damaging; tebapivat's discontinuation in both MDS and sickle cell in 2026 removed the main backup. The sickle cell decision, pushed to February 1, 2027, is binary, could come with a REMS that limits uptake, and accelerated approval would require a confirmatory trial that could still fail. Sickle cell and thalassemia are competitive markets with gene therapies, Novo Nordisk's etavopivat and other novel agents. Ongoing R&D and commercial spending will continue to burn cash, and while the balance sheet is solid today, sustained losses without pipeline success would eventually pressure it. CRSP: The commercial ramp of Casgevy has been far slower than early projections: CRSP's reported revenue was only about $3.5 million in all of 2025, down sharply from prior years that were boosted by one-time milestone payments, and only about $25 million over the twelve months to September 2026. The expiration of CRISPR's cost-deferral agreement with Vertex drove collaboration expenses up roughly 77 percent year over year in 2025, contributing to a full-year operating loss of approximately $665 million, and the company must repay around $222 million in previously deferred costs before net cash flows from Casgevy accrue to CRSP shareholders. Losses have not yet narrowed in a straight line: the Q3 2026 net loss of about $111 million was wider than Q2's and missed consensus. The convertible notes add about $780 million of debt that will eventually need to be repaid or converted, with dilution risk if conversion happens. Competing gene-editing and cell-therapy platforms from Intellia Therapeutics, Beam Therapeutics, and large pharmaceutical companies pursuing in vivo approaches could erode CRSP's differentiation over time. The share price, down about 36% over three months and near its 52-week low even after the November CTX310 update, reflects meaningful skepticism about the pace of the commercial ramp, and binary clinical readouts can move it sharply in either direction.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell AGIO or CRSP; figures are approximate and dated (as of November 2026). Verify current data before investing.